Alvotech stock analysis
Alvotech (Z45) Stock Price & Analysis
Z45 Stock Chart & Stats
- Day’s Range
- EUR 3.86 - EUR 3.96
- 52-Week Range
- EUR 2.52 - EUR 5.38
- Previous Close
- EUR 3.62
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 1.42B
- Enterprise Value
- EUR 3.57B
- Total Cash (Recent Filing)
- EUR 61.47M
- Total Debt (Recent Filing)
- EUR 1.56B
- Price to Earnings (P/E)
- ―
- Beta
- 0.58
- Next Earnings
- Mar 10, 2027 (Est.)
- EPS Estimate
- 0.15
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Improving Commercial Performance
The sharp increase in product revenue and adjusted EBITDA indicates improving commercial traction as established products and newer launches gain reach. If sustained, stronger product-led performance can reduce reliance on licensing timing and support better operating leverage over coming quarters.
Manufacturing Productivity
Higher output per batch allows Alvotech to produce equivalent volumes with fewer production runs, improving use of existing infrastructure and freeing capacity for additional biosimilars. This can strengthen supply reliability, support partner demand, and improve manufacturing economics over time.
Pipeline And Commercial Expansion
The Lotus partnership broadens Alvotech's pipeline exposure across oncology and rare-disease biosimilars while expanding geographic access. Potential milestone payments, supply revenue, and direct U.S. participation could diversify commercialization economics and increase the value captured from future launches.
Bears Say
High Leverage And Negative Equity
The combination of substantial debt and negative equity leaves Alvotech with limited financial flexibility. Leverage raises refinancing and interest burdens, constrains investment choices, and increases the consequences of operational delays or weaker product launches during the next several quarters.
Persistent Cash Burn
Recurring operating and free-cash-flow deficits mean the business has not yet funded its development and manufacturing needs internally. Continued cash burn increases dependence on external financing and makes the balance-sheet burden more material until management's expected cash-flow improvement is achieved.
Revenue And Margin Volatility
Declining revenue and compressed product margins demonstrate that scale has not yet translated into stable earnings power. Revenue timing, manufacturing recovery, and mix effects can continue to create volatility, making near-term profitability and cash generation less dependable despite pipeline progress.
Alvotech News
Z45 FAQ
What was Alvotech’s price range in the past 12 months?
What is Alvotech’s market cap?
When is Alvotech’s upcoming earnings report date?
How were Alvotech’s earnings last quarter?
Is Alvotech overvalued?
Does Alvotech pay dividends?
What is Alvotech’s EPS estimate?
How many shares outstanding does Alvotech have?
What happened to Alvotech’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Alvotech?
What is the TipRanks Smart Score and how is it calculated?
Alvotech Stock Smart Score
Company Description
Alvotech
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Lisa Graver
- Employees
- 1,279
- Website
- www.alvotech.com
- Address
- 9, Rue de Bitbourg, Luxembourg, LU, 1273, LU
Alvotech (Z45) Earnings & Revenues
Z45 Company Deck
Z45 Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, with strong Q3 product revenue and EBITDA growth, improving manufacturing capacity and productivity, multiple regulatory milestones, expanding commercial reach, strong stated demand, and expectations for Q4 recovery and 2027 deleveraging. These positives were tempered by a 23% nine-month revenue decline, ongoing supply ramp-up, cash use and high interest payments, a full-year outlook trending toward the lower end of guidance, compressed 2026 product margins, and patent-related launch uncertainty.
View all DE:Z45 earnings summariesZ45 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 5 | 10 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 4 | 0 | 8 |













